Lyra Therapeutics (LYRA) Shares Outstanding (Weighted Average) (2019 - 2025)
Quarterly Shares Outstanding (Weighted Average) rose 19.29% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 19.29% year-over-year, with the annual reading at $1.6 million for FY2025, 19.29% up from the prior year.
Lyra Therapeutics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $1.6 million for Q4 2025.
- Shares Outstanding (Weighted Average) came in at $1.6 million for Q4 2025, up from $1.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $64.0 million in Q1 2024 to a low of $200612.0 in Q4 2023.
- The 5-year median for Shares Outstanding (Weighted Average) is $13.0 million (2021), against an average of $17.8 million.
- Year-over-year, Shares Outstanding (Weighted Average) surged 5507.53% in 2021 and then plummeted 97.04% in 2024.
- Lyra Therapeutics' Shares Outstanding (Weighted Average) stood at $13.0 million in 2021, then crashed by 61.5% to $5.0 million in 2022, then crashed by 95.99% to $200612.0 in 2023, then skyrocketed by 549.15% to $1.3 million in 2024, then rose by 19.29% to $1.6 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Shares Outstanding (Weighted Average) are $1.6 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Lyra Therapeutics | - | - | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 8.61 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 8.61 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | 200,612.00 |
| Sep 30, 2023 | 56.95 Mn |
| Jun 30, 2023 | 43.68 Mn |
| Mar 31, 2023 | 36.83 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 36.83 Mn |
| Jun 30, 2022 | 23.54 Mn |
| Mar 31, 2022 | 13.01 Mn |
| Dec 31, 2021 | 12.99 Mn |
| Sep 30, 2021 | 13.00 Mn |
| Jun 30, 2021 | 12.97 Mn |
| Mar 31, 2021 | 12.95 Mn |
| Dec 31, 2020 | 8.59 Mn |
| Sep 30, 2020 | 12.92 Mn |
| Jun 30, 2020 | 4.21 Mn |
| Mar 31, 2020 | 230,860.00 |
| Dec 31, 2019 | 202,093.00 |
| Sep 30, 2019 | 192,433.00 |
| Jun 30, 2019 | 177,962.00 |
| Mar 31, 2019 | 170,156.00 |